
Man dies after being sucked into MRI machine by his own metal necklace
A man who was violently sucked into an MRI machine by a metal chain around his neck has died, police in New York said.
The man was wearing a large metallic chain around his neck, which caused him to be drawn into the machine, the Nassau County Police Department said in a news release. The incident took place at the Nassau Open MRI medical facility in the village of Westbury on the North Shore of Long Island.
Police responded to the facility just after 4:30 p.m. on July 16. At the scene, witnesses told officers a 61-year-old man "entered an unauthorized M.R.I. room while the scan was in progress," police said.
Multiple injuries in incident: Over 2 dozen people injured after vehicle crashes into crowd in Los Angeles
He was transported to a local hospital where he was initially listed in critical condition. He died at the hospital on July 17 at 2:36 p.m., police said.
Officials have not yet released the name of the man nor whether he was a visitor to the facility, a patient or if he worked there. Police did not elaborate on the type or extent of the man's injuries.
Man drawn into MRI from 'a large metallic chain around his neck'
According to police, the machine's magnetic field immediately attracted "a large metallic chain" the victim wore, which quickly pulled him into the machine and "resulted in a medical episode."
The investigation into the incident is ongoing, police said.
USA TODAY contacted Nassau Open MRI on July 18 but has not received a response.
MRI risks may include 'injuries from projectiles'
Magnetic resonance imaging, or MRI, is a non-invasive 3D imaging technology used to examine patients' organs, tissues and skeletal system for diagnostic purposes, according to the Mayo Clinic.
Adverse events from MRI scans "are rare," according to the U.S. Food and Drug Administration (FDA), which regulates MRI equipment.
Millions of MRI scans are performed across the nation every year, the FDA wrote on its website. The agency said it receives around 300 incident reports annually involving MRI scanners and coils from manufacturers, distributors, user facilities and patients.
Most of the reports, according to the FDA, include burns, as well as injuries from "projectile events" (objects being drawn toward the MRI scanner). High-powered magnets in the machine quickly draw items, especially metal, into the machine's chamber.
"The strong magnetic field can attract metallic objects, potentially causing them to become projectiles and injure patients," the FDA's website reads.
The magnetic force "is strong enough to fling a wheelchair across a room," according to the National Institute of Biomedical Imaging and Bioengineering. "Patients should notify their physicians of any form of medical or implant prior to an MR scan."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
an hour ago
- USA Today
Family of man sucked into MRI machine speaks on 'heartbreaking incident'
"He was a friend to many," Keith McAllister's stepdaughter said. The family of a man who died after being sucked into an MRI machine by a large metallic chain around his neck has spoken out. Keith McAllister, 61, was "tragically killed" on July 16 when he went to visit a Magnetic Resonance Imaging (MRI) medical facility in Westbury, New York, according to the Nassau County Police Department and a GoFundMe started by the man's family. McAllister succumbed to his injuries at a local hospital on July 17 at 2:36 p.m., according to police. Family issues statement on tragic incident The McAllister family's attorney, Michael Lauterborn, shared a statement with USA TODAY on Thursday, July 24. "The McAllister family and their friends are deeply saddened by the tragic loss of Mr. Keith McAllister, who passed away following a preventable incident at Nassau Open MRI in Westbury, New York," the statement reads. "We ask the public and friends to keep Mr. McAllister's wife, Adrienne Jones-McAllister, and the entire family in their thoughts and prayers during this profoundly difficult time. The family is truly grateful for the outpouring of heartfelt condolences received from the community and from across the country." According to the family's statement, they and their attorneys are "ensuring that all facts surrounding this incident" are being investigated by police and the New York State Department of Health. "This heartbreaking incident highlights the critical importance of safety protocols in medical imaging facilities," the statement continues. "The family and our legal team are dedicated to assisting the appropriate authorities in their investigation and in efforts to ensure accountability and prevent similar tragedies in the future." Who was Keith McAllister? The GoFundMe created by McAllister's stepdaughter, Samantha Bodden, says he was "a husband, a father, a stepfather, a grandfather, a brother and an uncle." "He was a friend to many," Bodden wrote on the fundraiser page. According to Bodden, her mother was lying on the table for the MRI when the technician left the room to get McAllister to help get her up. During this moment, the technician allegedly forgot to tell McAllister to remove the chain around his neck, his stepdaughter wrote. "My mother and the tech tried for several minutes to release him before the police were called," Bodden wrote. "He was attached to the machine for almost an hour before they could release the chain from the machine." McAllister died after suffering several heart attacks following the incident, according to his stepdaughter. Now, the family is asking for donations to bury him, she added. As of Thursday, July 24, the family has received over $11,000 in donations, only about a $1,000 shy of the GoFundMe's goal of $12,000. Adrienne Jones-McAllister saw MRI machine 'snatch' husband McAllister's wife, Adrienne Jones-McAllister, told News 12 Long Island that she recalled her husband walking toward the MRI table and seeing the machine "snatch him." "He went limp in my arms, and this is still pulsating in my brain," she said, per the TV station. Jones-McAllister said she had an MRI on her knee and needed help getting up from the table, according to News 12 Long Island. Her husband came into the room wearing the 20-pound chain that he wears for weight training purposes, she told the TV station. "That was not the first time that guy has seen that chain. They had a conversation about it before," Jones-McAllister said about the MRI technician's prior knowledge of her husband's chain. Contributing: Natalie Neysa Alund and Mike Snider, USA TODAY Jonathan Limehouse covers breaking and trending news for USA TODAY. Reach him at JLimehouse@

Business Upturn
an hour ago
- Business Upturn
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
By Business Wire India Published on July 24, 2025, 21:59 IST Business Wire India ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S. 1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease. 2,3 The approval represents an important milestone for LEO Pharma's expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs. LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.1 ANZUPGO is an innovative steroid-free, topical pan-Janus kinase (JAK) inhibitor for adults with CHE.1 ANZUPGO inhibits the JAK-STAT pathway, specifically blocking the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), and suppresses the various inflammatory responses that play a key role in the onset and subsequent flares of CHE.1,2,4 The FDA approval of ANZUPGO marks a significant milestone in LEO Pharma's strategy to expand its presence in the U.S. market and deliver purposeful innovation in skin health. In preparation for bringing ANZUPGO to the U.S. patients, LEO Pharma has significantly upscaled its operations across key functions – including a 50% increase in the sales force. 'ANZUPGOis a good example of how we transform a real need in the market into medicines that can help make a difference for people living with serious skin diseases such as CHE,' said Christophe Bourdon, CEO, LEO Pharma. 'After successfully launching ANZUPGOin several countries, we're proud to now bring this innovation to adult patients with moderate-to-severe CHE in the United States. The approval of ANZUPGO reinforces our commitment to investing in difficult-to-treat skin conditions to deliver new treatments to patients where the need is greatest. We're truly grateful to the patients and physicians who participated in our studies and helped make this approval possible.' CHE is a highly debilitating inflammatory skin disease that affects approximately one in ten adults worldwide, causing itchy, painful, blistered, or swollen skin that can interfere with daily activities.2,3,5,6 The FDA approval of ANZUPGO provides adults in the U.S. living with moderate-to-severe CHE with the first and only treatment option specifically approved for this skin disease, just as it will be the first and only topical pan-JAK-inhibitor on the U.S. market. 'Chronic hand eczema can be a very difficult disease for adults to manage, especially given the lack of treatment options in the U.S. until now,' said Robert Spurr, EVP and President, North America, LEO Pharma. 'As the first and only FDA-approved treatment specifically for CHE in the U.S., ANZUPGO further establishes our company's real commitment to bringing treatments to market that address unmet needs in medical dermatology.' The FDA approval is the latest regulatory milestone for ANZUPGO, following the European Commission (EC) approval in 2024 and several launches internationally, including Germany, Switzerland, the United Kingdom and the United Arab Emirates. *Ends* About ANZUPGO®(delgocitinib) Cream ANZUPGO® (delgocitinib) cream is currently FDA approved in the U.S. as the first and only treatment for chronic hand eczema (CHE). ANZUPGO is also approved in the European Union, United Kingdom, Switzerland and the United Arab Emirates for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or not advisable. ANZUPGO cream is also under investigation in other markets. Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended by the U.S. FDA.1 ANZUPGO cream is a topical pan-Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe CHE in adults. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.7 In 2014, LEO Pharma A/S and Japan Tobacco Inc. (JT) entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan, where JT retains rights. The full U.S. FDA Prescribing Information and Medication Guide are available here: About Chronic Hand Eczema Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for three or more months or relapses twice or more within a year.5,8 HE is one of the most common skin disorders of the hands and in a substantial number of patients, it can develop into a chronic condition.9 CHE affects approximately one in ten adults worldwide.2,3 It is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.6 The pathophysiology is characterized by skin barrier dysfunction, inflammation of the skin, and alterations of the skin microbiome.2 CHE has been shown to cause psychological and functional burdens that impact patient quality of life,10,11 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities.12 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.13 About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit References ANZUPGO® (delgocitinib) cream. Prescribing Information. FDA. July 2025. Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. Quaade AS, Simonsen AB, Halling A-S, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population – A systematic review and meta-analysis. Contact Dermatitis. 2021;84:361–374. Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64:41-51. Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360. Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378. Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233. Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22. Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20. Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984-991. Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168. Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626. MAT-84121 July 2025 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.


WebMD
2 hours ago
- WebMD
FDA OKs New Steroid-Free Skin Cream for Hand Eczema
July 24, 2025 – The FDA has approved a new treatment as the first and only skin cream for a specific type of hand eczema that affects about 1 in every 10 people globally. The cream, sold under the name Anzupgo, contains a new drug called delgocitinib and is for adults with long-term or chronic hand eczema (CHE), especially if steroid creams don't help or aren't a good option. CHE is a type of eczema that affects hands and wrists, causing the skin to become dry, itchy, sore, blistered, thick, or swollen. It can last for at least three months and flares up at least twice a year. CHE develops when the skin's protective barrier is damaged, leading to inflammation and changes in the naturally existing skin bacteria. CHE can seriously affect daily life and mental health as around 70% of people with severe CHE find it hard to do everyday tasks. Currently available treatments often provide only temporary relief, may cause side effects with long-term use, and may need to be injected, highlighting the need for effective and easy-to-use options. Anzupgo was tested in two studies with about 960 people who had moderate to severe CHE. They used either Anzupgo or a placebo cream twice a day for 16 weeks. More people who used Anzupgo had clear or almost clear skin (20% and 29%) compared to those who used the fake cream (10% and 7%). In a longer follow-up study, about 30% of patients using Anzupgo continued to see improvement after 36 weeks. Overall, the treatment was well-tolerated. Less than 1% of people reported side effects like mild skin pain, tingling, itching, redness, or skin infections. A few also had low white blood cell counts. Anzupgo, made by the drugmaker Leo Pharma, is a steroid-free cream that works by blocking key signals from specific proteins in the immune system known as JAK, which cause inflammation in the skin when overactivated. This helps reduce flare-ups and relieve symptoms. Patients can easily apply the cream to the affected areas only on their hands and wrists, following their doctor's advice, and avoid touching their mouth and eyes. The FDA advises against using Anzupgo alongside other medications that work in a similar way or suppress the immune system, as this could raise the risk of side effects. People using Anzupgo should also avoid live vaccines right before, during, and shortly after treatment. Breastfeeding women are told not to touch their nipple area after applying the cream to their hands or wrists. Doctors should be informed of any ongoing or frequent infections, as well as any other health conditions that might increase the risk of infection during treatment.